Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with COVID-19 - 10/06/22
, Pascal Bilbault b, Thibaut Fabacher c, Nicolas Lefebvre d, Sylvain Lescuyer e, Emmanuel Andres f, Elise Schmitt g, Sabrina Garnier-KepKA h, Pierrick Le Borgne i, Joris Muller j, Hamid Merdji k, Frédéric Chaffraix l, Didier Mutter m, Thomas F Baumert n, Ferhat Meziani o, Michel Doffoel p
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Highlights |
• | Abnormal liver tests at admission are associated with a poorer clinical outcome. |
• | Patients with metabolic syndrome and NAFLD related fibrosis have a higher risk of hospitalization. |
• | High FIB-4 index at admission may predict the risk to develop a moderate or severe disease. |
Abstract |
Background and aims |
Coronavirus disease 2019 (COVID-19) is a serious public health issue that became rapidly pandemic. Liver injury and comorbidities, including metabolic syndrome, are associated with severe forms of the disease. This study sought to investigate liver injury, clinical features, and risk factors in patients with mild, moderate, and severe COVID-19.
Methods |
We retrospectively included all consecutive patients hospitalized with laboratory-confirmed COVID-19 between February, 22 and May 15, 2020 at the emergency rooms of a French tertiary hospital. Medical history, symptoms, biological and imaging data were collected.
Results |
Among the 1381 hospitalizations for COVID-19, 719 patients underwent liver tests on admission and 496 (68.9%) patients displayed abnormal liver tests. Aspartate aminotransferase was most commonly abnormal in 57% of cases, followed by gamma-glutamyl transferase, alanine aminotransferase, albumin, alkaline phosphatase, and total bilirubin in 56.5%, 35.9%, 18.4%, 11.4%, and 5.8%. The presence of hepatocellular type more than 2xULN was associated with a higher risk of hospitalization and a worse course of severe disease (odd ratio [OR] 5.599; 95%CI: 1.27–23.86; p = 0.021; OR 3.404; 95% CI: 2.12–5.47; p < 0.001, respectively). A higher NAFLD fibrosis score was associated with a higher risk of hospitalization (OR 1.754; 95%CI: 1.27–2.43, p < 0.001). In multivariate analyses, patients with high fibrosis-4 index had a 3-fold greater risk of severe disease (p < 0.001).
Conclusion |
Abnormal liver tests are common in patients with COVID-19 and could predict the outcome. Patients with non-alcoholic fatty liver disease and liver fibrosis are at higher risk of progressing to severe COVID-19.
Il testo completo di questo articolo è disponibile in PDF.Keywords : SARS-CoV-2 infection, COVID-19 disease, Liver function tests (LFTs), Obesity, Liver steatosis, Liver fibrosis
Abbreviations : ALP, ALT, AST, BMI, COVID-19, FIB-4, GGT, HSI, LFTs, NAFLD, NFS, SaO2, SARS-CoV-2, TBIL, TP, ULN
Mappa
Vol 46 - N° 5
Articolo 101894- Maggio 2022 Ritorno al numero
Articolo precedente
- Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis
- Qin Shi, Jiacheng Liu, Tongqiang Li, Chen Zhou, Yingliang Wang, Songjiang Huang, Chongtu Yang, Yang Chen, Bin Xiong
- The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience
- Anna Boulouta, Ioanna Aggeletopoulou, Stavros Kanaloupitis, Efthymios P Tsounis, Vasileios Issaris, Konstantinos Papantoniou, Anastasios Apostolos, Paraskevas Tsaplaris, Ploutarchos Pastras, Christos Sotiropoulos, Aggeliki Tsintoni, Georgia Diamantopoulou, Konstantinos Thomopoulos, Marina Michalaki, Christos Triantos
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.